Oncaspar I.V. Infusion 3750 General Drug Use-Results Survey (Acute lymphocytic leukemia, malignant lymphoma)

Oncaspar I.V. Infusion 3750 General Drug Use-Results Survey (Acute lymphocytic leukemia, malignant lymphoma) - Oncaspar General Drug Use-Results Survey (Acute lymphocytic leukemia, malignant lymphoma)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000053191

Enrollment

180

Registered

2023-12-22

Start date

2024-01-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute lymphocytic leukemia, malignant lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with acute lymphoblastic leukemia or malignant lymphoma who are administered Oncaspar for the first time. In addition, patients who are given consent to participation in the survey.

Exclusion criteria

Exclusion criteria: No given consent to participation in the survey.

Design outcomes

Primary

Measure	Time frame
Overall incidence of each ADRs and AEs	—

Countries

Japan

Contacts

Public ContactSayoko KAWAMURA

NIHON SERVIER CO., LTD. DRUG SAFETY & REAL WORLD EVIDENCE

sayoko.kawamura@servier.com08056533878

Outcome results